2020
DOI: 10.1111/bjh.16485
|View full text |Cite
|
Sign up to set email alerts
|

Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
36
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 24 publications
(39 citation statements)
references
References 10 publications
2
36
1
Order By: Relevance
“…In summary, our results complement the currently limited literature [21][22][23]32] on the efficacy and safety of DOACtreated MPN patients. Despite the limitations-small number of patients, retrospective analysis, and short treatment timeour data suggest that the use of DOAC was as effective and safe as VKA.…”
Section: Discussionsupporting
confidence: 81%
“…In summary, our results complement the currently limited literature [21][22][23]32] on the efficacy and safety of DOACtreated MPN patients. Despite the limitations-small number of patients, retrospective analysis, and short treatment timeour data suggest that the use of DOAC was as effective and safe as VKA.…”
Section: Discussionsupporting
confidence: 81%
“…We demonstrated the efficacy of DOACs in this setting of patients: no thrombotic events were observed. We included patients at high thrombotic risk, such as patients with myeloproliferative disorders 48,49 and patients with MM on immunomodulant agents 5,9 . The use of DOACs appears to be effective in both VTE and AF; this is an important observation, considering that there is no solid evidence regarding how to manage AF in cancer patients 50 .…”
Section: Discussionmentioning
confidence: 99%
“…89 Very recently, two studies were published on this issue. 90,91 A retrospective English study evaluated 32 patients with MPN-associated VTE, including SVT and cerebral thrombosis, receiving DOACs (17 rivaroxaban, 14 apixaban, and 1 edoxaban). 90 During the follow-up, there were no VTE recurrences in 31 patients, and only one case had evidence of mesenteric ischemia.…”
Section: Direct Oral Anticoagulantsmentioning
confidence: 99%